top of page
Samantha Follen
Writer
More actions
Profile
Join date: Nov 2, 2023
Posts (2)
Oct 29, 2024 ∙ 5 min
FTC Endorses FDA’s Updated Biosimilar Interchangeability Guidelines: Enhancing Access or Creating New Uncertainty?
Photo by Louis Reed, downloaded from and available on Unsplash Biosimilars versus Biologics Biosimilars are a class of medications that provide safe and effective treatment for a wide range of illnesses includingchronic skin and bowel diseases, arthritis, and certain cancers. [1] Unlike traditional “small molecule” drugs, biologics are typically derived from living organisms like yeast and bacteria and are much more complex in terms of structure, composition, and manufacturing. [2] A...
102
0
Nov 2, 2023 ∙ 4 min
Navigating the Dense Patent Thicket and Its Grip on Drug Prices
[1] The patent system in the United States is intended to promote innovation and serve as the catalyst for creative inventions. [2] Specifically, patent rights have a substantial impact on the prescription drug industry; this impact is on both the development of new drugs as well as the pricing of such drugs. [3] Patents are desired by innovators because they give the patent holder “exclusivity” of their work. [4] This creates a “temporary monopoly” on the invention, which grants the...
107
0
bottom of page
